OneSource Specialty Pharma Limited has announced its audited financial results for the quarter and year ended March 31, 2026. The company reported annual standalone revenue of ₹14,203.89 million with a profit of ₹212.10 million. Additionally, the Board has approved the appointment of B S R & Co LLP as the new statutory auditor for a five-year term, succeeding Deloitte Haskins & Sells, effective from the conclusion of the 19th Annual General Meeting.
Financial Performance Overview
For the financial year ended March 31, 2026, OneSource Specialty Pharma reported a standalone revenue of ₹14,203.89 million, compared to ₹12,995.89 million in the previous fiscal year. The standalone net profit for the year stood at ₹212.10 million. On a consolidated basis, the group recorded revenue from operations of ₹14,215.90 million for the year, while navigating a consolidated net loss of ₹738.03 million.
Leadership in Auditing
In a major transition, the Board of Directors has appointed B S R & Co LLP as the company’s new statutory auditor. This appointment is for a term of five consecutive years, commencing from the conclusion of the 19th Annual General Meeting until the end of the 24th Annual General Meeting. This follows the completion of the tenure of Deloitte Haskins & Sells, which concludes at the upcoming annual general meeting. The appointment remains subject to the final approval of shareholders.
Corporate Developments
The company continues to advance its strategic growth plans. During the fiscal year, OneSource pursued a Composite Scheme of Arrangement and Amalgamation to streamline its business structure. Furthermore, the company successfully managed operational integration, including the finalization of the amalgamation of Stelis PTE Limited with OneSource Specialty PTE. Limited, which became effective on January 1, 2026. These initiatives are designed to consolidate operational capabilities and enhance the company’s focus within the Pharma and Life Sciences sector.
Source: BSE
